Mr. Neil Closner reports

MEDRELEAF ANNOUNCES RECEIPT OF INTERIM COURT ORDER AND MAILING OF MEETING MATERIALS FOR ARRANGEMENT WITH AURORA CANNABIS

Medreleaf Corp. has been granted an interim order from the Ontario Superior Court of Justice (commercial list) authorizing various matters, including the holding of a special meeting of Medreleaf shareholders to consider the previously announced arrangement between Medreleaf and Aurora Cannabis Inc. and the mailing of a management information circular in respect of the previously announced transaction, whereby Aurora intends to acquire all of the issued and outstanding common shares of Medreleaf.

As described in the circular, Medreleaf will be seeking shareholder approval for the arrangement under the Business Corporations Act (Ontario). The special meeting of Medreleaf shareholders to consider the arrangement resolution will be held on July 18, 2018, at 1 p.m. Toronto time at the offices of Stikeman Elliot LLP, 5300 Commerce Ct. West, 199 Bay St., Toronto, Ont. Medreleaf shareholders of record as of the close of business on June 14, 2018, are eligible to vote at the special meeting.

The board of directors of Medreleaf has unanimously recommended that Medreleaf shareholders vote for the arrangement resolution. Certain directors and officers of the company have entered into support agreements pursuant to which they have agreed to vote their shares in favour of the arrangement. In addition, holders of approximately 56 per cent of the company's issued and outstanding common shares have entered into irrevocable hard lock-ups to vote their shares in favour of the arrangement.

Under the terms of the arrangement, Medreleaf shareholders will be entitled to receive 3.575 common shares of Aurora and 0.0001 cent in cash in exchange for each Medreleaf common share held. Certain shareholders will also be entitled to elect to receive only the share consideration (and not to receive the cash consideration).

The circular has been mailed to the shareholders of Medreleaf, and will also be available under the profile of Medreleaf on SEDAR. It will also be available on the website of Medreleaf.

Your vote is important. Please vote today. Your vote is important regardless of the number of shares you own. Medreleaf shareholders are encouraged to read the circular in detail.

Shareholders who have questions regarding the arrangement or who require assistance with voting may contact D.F. King, the company's proxy solicitation agent, by telephone toll-free at 1-866-521-4425 (1-212-771-1133 by collect call) or by e-mail at inquiries@dfking.com.

About Medreleaf Corp.

Canada's most awarded licensed producer, Medreleaf is an R&D-(research and development)-driven company dedicated to innovation, operational excellence and the production of top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state-of-the-art ICH-GMP- and ISO 9001-certified facilities in Ontario, Canada, with a third facility currently in development, premium Medreleaf products are delivered to the global medical market. Medreleaf serves the therapeutic needs of patients seeking safe, consistent and effective medical cannabis and provides a compelling product offering for the adult-use recreational consumer.

We seek Safe Harbor.